

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



# 石四藥集團有限公司 SSY Group Limited

*(Incorporated in the Cayman Islands with limited liability)*  
(Stock Code: 2005)

## PRE-LISTING TUTORING APPLICATION IN RELATION TO PROPOSED LISTING OF JIANGSU BEST NEW MEDICAL ON THE BEIJING STOCK EXCHANGE

References are made to the announcements of SSY Group Limited (the “**Company**”) dated 6 July 2022, 28 April 2022, 28 January 2022, 13 December 2021 and 18 October 2021 (the “**Announcements**”) in relation to the spin-off and separate quotation of the shares of Jiangsu Best New Medical Material Co., Ltd.\* (江蘇博生醫用新材料股份有限公司) (“**Jiangsu Best New Medical**”) on the National Equities Exchange and Quotations (the “**NEEQ**”). Capitalised terms used herein shall have the same meaning as those defined in the Announcements, unless the context requires otherwise.

As disclosed in the Announcements, it has been the intention of the Company to seek a separate listing of the shares of Jiangsu Best New Medical on the Beijing Stock Exchange subsequent to the completion of the spin-off and separate quotation of the shares of Jiangsu Best New Medical on the NEEQ.

Following the quotation of the shares of Jiangsu Best New Medical (Stock Code: 873710) on the NEEQ on 7 July 2022, the Company is pleased to announce that preliminary preparation has been initiated for a potential transfer of the listing of Jiangsu Best New Medical to the Beijing Stock Exchange (the “**Proposed Listing**”).

On 14 April 2023, Jiangsu Best New Medical submitted an application for a pre-listing tutoring process in connection with the Proposed Listing with the Jiangsu Securities Regulatory Bureau of the China Securities Regulatory Commission.

As at the date of this announcement, no application for the Proposed Listing has been made to the Beijing Stock Exchange and no final decision has been made as to whether and/or when to proceed with the Proposed Listing.

The Company has made an application to the Stock Exchange for, and the Stock Exchange has confirmed that the Company may proceed with, the spin-off and separate quotation of the shares of Jiangsu Best New Medical on the NEEQ in compliance with Practice Note 15 of the Listing Rules. Therefore, the Company considers that it is not required to make another application under Practice Note 15 of the Listing Rules for the Proposed Listing, which encompasses the potential transfer of the listing of Jiangsu Best New Medical (being a previously spun off entity) to the Beijing Stock Exchange.

If the Proposed Listing is proceeded with, depending on the fundraising structure, it may or may not constitute a notifiable transaction of the Company under Chapter 14 of the Listing Rules. The Company will comply with the Listing Rules and make further announcements in connection with the Proposed Listing as and when appropriate or required under the Listing Rules.

**As of the date of this announcement, the Proposed Listing is at a preliminary stage. Shareholders and potential investors of the Company and Jiangsu Best New Medical should note that the implementation of the Proposed Listing is subject to, amongst other things, market conditions, approvals from the relevant regulatory authorities (including but not limited to the Beijing Stock Exchange) and the final decision made by the Company and Jiangsu Best New Medical. There is no assurance as to when the Proposed Listing will take place, or if it will take place at all. Accordingly, shareholders of the Company and potential investors of the Company and Jiangsu Best New Medical are reminded to exercise caution when dealing in the securities of the Company and Jiangsu Best New Medical.**

By order of the Board

**Chow Hing Yeung**

*Executive Director and Company Secretary*

Hong Kong, 14 April 2023

*As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Su Xuejun, Mr. Meng Guo and Mr. Chow Hing Yeung as executive Directors, Mr. Feng Hao as non-executive Director and Mr. Wang Yibing, Mr. Leung Chong Shun, Mr. Chow Kwok Wai and Mr. Jiang Guangce as independent non-executive Directors*

\* *for identification purpose only*